Aastrom arranges $3.8 million at-the-market issuance sales agreement

Offering will be conducted by agent MLV

By Devika Patel

Knoxville, Tenn., June 27 – Aastrom Biosciences Inc. negotiated a $3.8 million at-the-market issuance sales agreement with MLV & Co. LLC, according to a prospectus supplement filed Friday with the Securities and Exchange Commission.

MLV will be paid a 3% commission.

Proceeds will be used for commercialization and development, working capital and general corporate purposes.

Aastrom is a biotechnology company based in Ann Arbor, Mich.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.